Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou, Tao Jiang
Abstract
Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).
Topics & Concepts
ImmunotherapyMedicineCancerCancer immunotherapyComputational biologyOncologyBiologyInternal medicineCancer Immunotherapy and BiomarkersPeptidase Inhibition and AnalysisCancer Mechanisms and Therapy